Significant New Data

Advanced Medical Solutions Grp PLC
14 November 2006


For immediate release                                           14 November 2006




                      Advanced Medical Solutions Group plc

                            ('AMS' or 'the Company')



                MULTI-CENTRE CLINICAL EVALUATION OF ACTIVHEAL(R)

       EQUIVALENT EFFICACY DEMONSTRATED OVER LEADING COMPETITOR PRODUCTS

                                      AND

         SUSTAINED ANTIMICROBIAL ACTIVITY FOR SILVER ALGINATE DRESSINGS



Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global
medical technology company, announces that new and significant clinical and
scientific study findings relating to the effectiveness of AMS' products, and
the resultant substantial time and cost savings to the NHS, will be presented
today in two posters at the Wounds UK 2006 Wound Care Conference in Harrogate.
The conference is being held from 13-15 November 2006.



Findings presented in one poster entitled 'A Summary of UK Evaluation of the
ActivHeal(R) Range of First Line Dressings', confirmed that substantial cost
savings to the NHS can be achieved through the use of AMS products.  Data from
multi-centre clinical evaluations showed that 98% of ActivHeal(R) woundcare
responses were equivalent to or better than responses from other dressings.
Whilst independent laboratory test have previously shown that the ActivHeal(R)
range has comparable physical properties to market leaders this new information
strongly endorses the clinical effectiveness of AMS' products.



The study data was collated from more than 150 applications from 9 Trusts,
including 5 hospitals and 4 Primary Care Trusts.



Savings achieved by using the ActivHeal(R) range as a first line therapy can be
made at a time when there is severe pressure on woundcare budgets, freeing up
funds for treating chronic wounds and for new technologies.  ActivHeal(R)
consist of alginate, hydrocolloid, hydrogel and foam dressings and is designed
to offer cost effective first line treatment of general wounds.



The second poster entitled '21 Day InVitro Study of Sustained Antimicrobial
Activity of a New Silver Alginate Dressing' relates to a study of the
antimicrobial properties of a new AMS silver alginate compared with those of a
leading brand in combating a variety of micro-organisms frequently found in
wounds, including antibiotic-resistant pathogens, such as MRSA, over an extended
period of up to 21 days.



This study concluded that both the AMS silver alginate and leading brand were
proven to provide sustained antimicrobial action against the test organisms up
to 14 days.  After this period, whilst the antimicrobial action of the leading
brand diminished significantly, the AMS silver alginate continued to kill the
test organisms for up to the 21 day completion of the study.   This study
indicates that the AMS silver alginate provides a sustained level of
antimicrobial activity.  This, combined with the inherent absorbency of the
dressing, may reduce dressing change frequency, and hence minimise pain and
trauma to the patient.  The silver alginate reduces the time and overall cost of
treatment and gives a better opportunity for healing to progress undisturbed.



Commenting on today's announcement Dr. Don Evans, Chief Executive of AMS,
stated:

'This new information is of key significance to the business.  The multi-centre
evaluation confirms that Activheal(R) offers the NHS a cost effective range of
first line woundcare dressings whilst providing comparable or even beneficial
clinical performance.  The results of this study have enabled clinicians from a
number of the Trusts involved to start using some or all of the dressings from
the ActivHeal(R) range.  AMS now supplies more than 20 hospital trusts and we
hope to grow this number further.



'The results of the silver alginate study will allow us to strengthen our
marketing claims for this product and we look forward to progressing this
through regulatory approvals.   Both of the posters presented in Harrogate
underline AMS' ability to deliver both innovation and cost management solutions
to the woundcare market.'



Copies of the posters described above are available from the Company's website
at www.admedsol.com or from Buchanan Communications.



                                     -ENDS-





For further information, please contact:


Advanced Medical Solutions Group plc                   Tel : [phone]
Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com

Buchanan Communications                                Tel: [phone]
Mark Court, Mary-Jane Johnson



Notes to Editors:



Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $13 billion global woundcare market. Founded in
1991 and currently quoted on AIM, Advanced Medical Solutions is focused on the
design, development and manufacture of innovative and technologically advanced
products for woundcare and other medical applications.



In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.



The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives that offer benefits over sutures and
staples for closing wounds sold direct to hospitals or through distributors.



AMS's technology and products currently serve the majority of the key global
markets and strategic partners.






                      This information is provided by RNS
            The company news service from the London Stock Exchange